{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Waco",
      "state": "TX",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "77143",
      "recalling_firm": "Allergan Sales, LLC",
      "address_1": "8301 Mars Dr",
      "address_2": "N/A",
      "postal_code": "76712-6578",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide in the US",
      "recall_number": "D-0929-2017",
      "product_description": "Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX only, Manufactured by Allergan, Irvine, California, 92612, U.S.A., NDC: 0023-0313-04.",
      "product_quantity": "648 units",
      "reason_for_recall": "Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.",
      "recall_initiation_date": "20170501",
      "center_classification_date": "20170629",
      "termination_date": "20190501",
      "report_date": "20170705",
      "code_info": "Lot: 93802, EXP NOV 2019"
    }
  ]
}